RDNT RadNet Inc.

RadNet’s Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety

RadNet’s Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety

  • DeepHealth and CARPL.ai have established a strategic collaboration to create a unique Artificial Intelligence (AI) control system for image interpretation to ensure AI scalability, performance monitoring, and safety, with the aim to accelerate the adoption of AI. 



  • DeepHealth currently monitors the performance of DeepHealth’s SmartMammo™ AI-powered solution for breast cancer detection at RadNet. Through the collaboration, the two companies aim to expand, productize and scale this control system across more applications to other customers.



  • Furthermore, DeepHealth will embed CARPL.ai’s cutting-edge AI orchestration capabilities that enable easy selection, implementation, and monitoring of appropriate AI models within DeepHealth’s cloud-native operating system, DeepHealth OS.

LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced a strategic collaboration with CARPL.ai, a leading AI orchestration company that enables radiologists to access, assess, and integrate radiology AI solutions in their workflows. DeepHealth will use CARPL.ai’s technology to develop an AI control system that can be commercialized and will be designed to monitor and optimize imaging AI performance for improved clinical outcomes, operational efficiency, and accelerated adoption of AI in radiology. AI monitoring is crucial to ensure reliable, accurate, and unbiased performance.

The two companies will collaborate on a new closed-loop AI feedback system that will continually monitor AI model accuracy and relevance in clinical settings. The system will automate the measurement and monitoring of performance and safety metrics such as specificity, sensitivity, data- and model drift.

Establishing a robust AI infrastructure with monitoring tools is key for safe, effective, and scalable AI adoption in radiology. While the current landscape is marked by an overwhelming array of AI-enabled point solutions, the future involves running multiple AI models, even for a single use case. DeepHealth’s partnership with CARPL.ai addresses this very need by creating a unique environment to dynamically run a combination of models and monitor performance and then continuously optimize the best models for specific tasks,” said Sham Sokka, PhD, Chief Operating and Technology Officer, DeepHealth.

The partnership will also combine CARPL.ai’s AI marketplace and orchestration platform, which offers a simplified process for selecting, implementing, and monitoring third-party FDA-cleared AI models, with DeepHealth’s cloud-native operating system, DeepHealth OS, which unifies data across the clinical and operational workflows. These platforms will be integrated and extended to monitor real-world workflows on an ongoing basis. The aim is to enable radiologists to access performant and safe AI interpretation tools deeply integrated in their workflows.

We are very excited to partner with DeepHealth to harness the transformative potential of AI within the radiology care continuum, particularly through workflow automation and clinical assistance. This new AI infrastructure is set to fundamentally redefine radiology by making AI an integral component of the system,” said Dr. Vidur Mahajan, CEO of CARPL.ai. “Monitoring AI performance is essential to ensure the reliability and accuracy of AI applications over time, and our technology enables real-time performance monitoring of both their accuracy and consistency for safe and effective use of AI in clinical practice.

For more information, visit the DeepHealth (#1340) and CARPL.ai (#5733) booths at the Radiological Society of North America 2024 Annual Meeting.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit .

About DeepHealth

DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth’s portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. 

About CARPL.ai

CARPL.ai is a vendor-neutral Artificial Intelligence (AI) platform that allows radiologists to access, assess, and integrate radiology AI solutions in their clinical practice.

CARPL provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows.

We are the world’s largest radiology AI marketplace offering 140+ applications from 60+ AI vendors.

For more information, visit /.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, CARPL.ai, and DeepHealth’s informatics, hardware and software product portfolios and the collaboration’s impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

For media inquiries, reach out to:

DeepHealth

Andra Axente

Communications Director

Phone:

Email:

RadNet, Inc.

Mark Stolper

Executive Vice President and Chief Financial Officer

310-445-2800

CARPL.ai

Shruti Singhal

Director – Marketing



EN
01/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RadNet Inc.

 PRESS RELEASE

RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of...

RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality...

 PRESS RELEASE

Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Gr...

Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Add RadNet’s AI-Powered Enhanced Breast Cancer Detection (EBCD) Program to its Membership Benefits in Southern California Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelinesRegal Medical Group, Lakeside Community Healthcare and ADOC Medical Group are affiliates of one of Southern California’s largest health networks, which manages nearly 600,000 members from newborns to Medicare recipientsRegal Medical Group, Lakesi...

 PRESS RELEASE

RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions...

RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has entered into Incremental Amendment No. 2 (the “Second Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, as amended by the Second Amendment, the “Credit Agreement”). Pursuant to the Se...

Radnet Inc: 1 director

A director at Radnet Inc sold 11,132 shares at 58.050USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Power...

RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics See-Mode’s commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet’s DeepHealth population health solutionsReal-world deployment of See-Mode’s FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI innovation in ultrasound LOS ANGELES, June 04, 2025 (GLOBE NE...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch